Trial · NCT05139095
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
NCT05139095, Phase 2, Recruiting, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia. Trials, record NCT05139095. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05139095
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
- NCT number
- NCT05139095
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Gestational Trophoblastic Neoplasia
- Interventions
- Camrelizumab plus apatinib CohortA, Camrelizumab plus apatinib Cohort B
- First posted
- 2021-12-01
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort A: Complete remission rate | up to one year | The proportion of patients achieving complete remission. Complete remission is defined as normal serum β-hCG level measured for 3 consecutive weeks. |
| Primary | Cohort B: Objective response rate | up to one year | The proportion of patients with complete or partial response according to serum β-hCG level. Partial response is defined as a ≥50% decrease in β-hCG level from baseline after 2 cycles. |
| Secondary | Cohort A: Objective response rate | up to one year | The proportion of patients with complete or partial response according to serum β-hCG level. |
| Secondary | Cohort A: Progression-free survival | up to one year | The time from the treatment initiation to disease progression or death, whichever comes first. Disease progression is defined as any increase in serum β-hCG level from baseline after 2 cycles of treatment or the presence of new metastatic lesions. |
| Secondary | Cohort A: Overall survival | up to one year | The time from the treatment initiation to the date of death or last follow-up. |
| Secondary | Cohort A: Duration of response | up to one year | The time from the first evidence of response to disease progression or death, whichever comes first. |
| Secondary | Cohort A: Frequency and severity of adverse events | up to one year | Determine frequency and severity of adverse events as assessed by NCI CTCAE (Version 5.0) which is used to evaluate the grade of adverse events, to observe any adverse event and serious adverse event that occurred in all patients during the clinical study period, including abnormal laboratory examination results, clinical manifestations and vital signs, to record their clinical manifestation characteristics, severity, occurrence time, duration, corresponding treatment and prognosis, and to determine their relationship with the study drug. |
| Secondary | Cohort B: Progression-free survival | up to one year | The time from the treatment initiation to disease progression or death, whichever comes first. |
| Secondary | Cohort B: Duration of response | up to one year | The time from the first evidence of response to disease progression or death, whichever comes first. |
| Secondary | Cohort B: Overall survival | up to one year | The time from the treatment initiation to the date of death or last follow-up. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05139095
GET https://conductscience.org/api/trials/v1/NCT05139095/registered